LYEL VS IRMD Stock Comparison

PerformanceTechnicalsEarningsProfitVolatilityAnalyst Price TargetsSentimentDividend
PerformanceTechnicalsEarningsProfitVolatilityAnalyst Price TargetsSentimentDividend

Performance

LYEL
10/100

LYEL returned -58.96% in the last 12 months. Based on SPY's performance of -13.12%, its performance is below average giving it a score of 10 of 100.

IRMD
100/100

IRMD returned 49.86% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 100 of 100.

Technicals

LYEL
54/100

LYEL receives a 53 of 100 based on 14 indicators. 7 are bullish, 6 are bearish.

IRMD
71/100

IRMD receives a 71 of 100 based on 14 indicators. 9 are bullish, 3 are bearish.

Earnings

LYEL
100/100

LYEL has missed earnings 1 times in the last 20 quarters.

IRMD
100/100

IRMD has missed earnings 1 times in the last 20 quarters.

Profit

LYEL
10/100

Out of the last 15 quarters, LYEL has had 0 profitable quarters and has increased their profits year over year on 0 of them.

IRMD
75/100

Out of the last 20 quarters, IRMD has had 18 profitable quarters and has increased their profits year over year on 8 of them.

Volatility

LYEL
43/100

LYEL has had a lower than average amount of volatility over the last 12 months giving it a score of 43 of 100.

IRMD
63/100

IRMD has had a higher than average amount of volatility over the last 12 months giving it a score of 62 of 100.

Analyst Price Targets

LYEL

"Analyst Price Targets" not found for LYEL

IRMD
63/100

2 analysts offer 12-month price targets for IRMD. Together, they have an average target of 0, the most optimistic target put IRMD at 0 within 12-months and the most pessimistic has IRMD at 0.

Sentiment

LYEL

"Sentiment" not found for LYEL

IRMD
71/100

IRMD had a bullish sentiment score of 70.64% across Twitter and StockTwits over the last 12 months. It had an average of 2.44 posts, 0.00 comments, and 0.00 likes per day.

Dividend

LYEL

"Dividend" not found for LYEL

IRMD
10/100

IRMD's most recent dividend was $1.00 per share, based on a share price of $42.74. It was a payout ratio of 505.05% compared to their total earnings.

All score calculations are broken down here to help you make more informed investing decisions

Lyell Immunopharma, Inc. Common Stock Summary

Nasdaq / LYEL
Healthcare
Biotechnology
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

iRadimed Corporation Summary

Nasdaq / IRMD
Healthcare
Medical - Devices
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.